Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 5

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 5
---
 the terms of a securities purchase agreement dated as of August 2, 2024 (the “August 2024 Purchase Agreement”) between us and the August 2024 Investor; (ii) 1,302,082 shares of Common Stock issuable upon the exercise of common warrants to purchase shares of Common Stock (the “Inducement Warrants”) purchased by certain existing warrant holders (the “Warrant Inducement Holders”) in a private placement transaction (the “Warrant Inducement”) pursuant to the terms of a warrant inducement letter agreement, dated as of August 2, 2024 (the “August Inducement Agreement”), between us and the Warrant Inducement Holders; and (iii) 49,862 shares of Common Stock issuable upon the exercise of warrants to purchase shares of Common Stock issued to designees of WallachBeth, of which (a) 39,062 shares of Common Stock issuable upon the exercise of warrants (the “Inducement Advisor Warrants”) to purchase shares of Common Stock were partial compensation for WallachBeth acting as financial advisor in connection with the Warrant Inducement and (b) 10,800 shares of Common Stock issuable upon the exercise of warrants (the “August 2024 PA Warrants” and, together with the August 2024 Common Warrants, the Inducement Warrants and the Inducement Advisor Warrants, the “August 2024 Warrants”) to purchase shares of Common Stock were partial compensation for WallachBeth acting as placement agent in connection with the August 2024 Private Placement. Each of the August 2024 Private Placement and the Warrant Inducement closed on August 5, 2024. As of June 27, 2025, August 2024 Warrants to purchase 499,862 shares of Common Stock remain outstanding and unexercised.

On November 27, 2024, we filed a Registration Statement on Form S-1 (Registration No. 333-283521), which was subsequently declared effective by the SEC on December 6, 2024 (the “December 2024 Registration Statement”), relating to the resale from time to time of up to 2,724,230 shares of Common Stock by the selling stockholders identified therein,including their pledgees, assignees, donees, transferees or their respective successors-in-interest consisting of: (i) 2,662,782 shares of Common